Oral levonantradol in the control of cancer chemotherapy-induced emesis.

abstract：:Fifty-one patients with non-small cell lung cancer (NSCLC) were treated, during a phase II trial, with 4'demethylepipodophyllotoxin-beta-D-ethylidene glucoside (VP16-213). Forty-nine were evaluable for response, and of these two (4%) had partial responses lasting 5 and 6 months. Prior treatment with chemotherapy may h...

journal_title：Cancer chemotherapy and pharmacology

authors： Chapman R,Itri L,Gralla R,Kelsen D,Casper E,Golbey R

更新日期：1982-01-01 00:00:00

abstract：PURPOSE:The study mainly aimed to determine the biological function of a novelly synthesized phenanthroimidazole derivative, named L233, and to explore its potential mechanisms. METHODS:Cell survival was examined using the MTT assays, and the DNA-damaging role of L233 was explored using the comet assay. Moreover, the ...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhen N,Yang Q,Wu Q,Zhu X,Wang Y,Sun F,Mei W,Yu Y

更新日期：2016-01-01 00:00:00

abstract：:KW-2149, a new mitomycin C (MMC) derivative, inhibited the growth of murine P388 leukemia in vitro at 20-fold lower concentrations than those of MMC. KW-2149 was also effective in inhibiting the growth of MMC-resistant P388 (P388/MMC) cells. To elucidate these characteristics of KW-2149, its uptake and efflux were com...

journal_title：Cancer chemotherapy and pharmacology

authors： Kobayashi E,Okabe M,Kono M,Arai H,Kasai M,Gomi K,Lee JH,Inaba M,Tsuruo T

更新日期：1993-01-01 00:00:00

abstract：:Aging influences the disposition and effects of several classes of drugs. Although drug clearance rate is correlated with toxicity for many anticancer drugs, few data have been published concerning the relationship of aging and clearance of chemotherapy. This study was performed to identify any relationship between ag...

journal_title：Cancer chemotherapy and pharmacology

authors： Borkowski JM,Duerr M,Donehower RC,Rowinsky EK,Chen TL,Ettinger DS,Grochow LB

更新日期：1994-01-01 00:00:00

abstract：:Pancreatic cancer is the fourth leading cause of cancer-related deaths in the USA, with a 5-year survival rate of 6 %. Anti-hyperglycemic treatments for type 2 diabetes mellitus that induce hyperinsulinemia (i.e., sulfonylureas) are thought to increase cancer risk, whereas treatments that lower insulin resistance and ...

journal_title：Cancer chemotherapy and pharmacology

authors： De Souza A,Khawaja KI,Masud F,Saif MW

更新日期：2016-02-01 00:00:00

abstract：:The purpose of this study was to assess the efficacy of verapamil (20 microM) and hyperthermia (42 degrees C) as modifiers of mitomycin C (MMC), used at different concentrations, in inhibiting the growth of human gastric adenocarcinoma (AGS) cells. Combined verapamil and hyperthermia treatment resulted in a significan...

journal_title：Cancer chemotherapy and pharmacology

authors： Shchepotin IB,Buras RR,Nauta RJ,Shabahang M,Evans SR

更新日期：1994-01-01 00:00:00

abstract：:The pharmacokinetics of doxorubicin (DOX) and doxorubicinol (DOXol) was studied in six patients with various advanced neoplastic diseases who received 28-72 mg/m2 DOX (nine courses). Plasma and parotid saliva were collected over a 48-h period, and DOX and DOXol were quantified by high-performance liquid chromatography...

journal_title：Cancer chemotherapy and pharmacology

authors： Bressolle F,Jacquet JM,Galtier M,Jourdan J,Donadio D,Rossi JF

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:Fenretinide is a synthetic retinoid with activity in prostate cancer and other cell lines. The aim of this study was to assess the efficacy and tolerability of fenretinide in chemotherapy-naïve men with hormone refractory prostate cancer. METHODS:Eligibility criteria included hormone refractory prostate cancer...

journal_title：Cancer chemotherapy and pharmacology

authors： Moore MM,Stockler M,Lim R,Mok TS,Millward M,Boyer MJ

更新日期：2010-10-01 00:00:00

abstract：:The subjects were 35 patients with unresectable hepatocellular carcinoma. The patients were divided into a transcatheter arterial embolization group (TAE group, 18 cases) and a combination therapy group receiving both TAE and percutaneous ethanol injection therapy (TAE+PEIT group, 17 cases). The 50% survival period wa...

journal_title：Cancer chemotherapy and pharmacology

authors： Tateishi H,Kinuta M,Furukawa J,Takata N,Maruyama H,Oi H,Yayoi E,Okamura J

更新日期：1994-01-01 00:00:00

abstract：:In this review of the management of invasive carcinoma of the bladder the results of primary and systemic therapies are evaluated in the light of the natural history of the disease. The clinical and pathological causes of treatment failure are assessed in an attempt to identify new approaches that may be used in the f...

journal_title：Cancer chemotherapy and pharmacology

authors： Bush H,Thatcher N,Barnard R

更新日期：1979-01-01 00:00:00

abstract：PURPOSE:Ifosfamide is a cornerstone of chemotherapy in bone and soft-tissue sarcoma. Results of pharmacokinetic studies indicate that the optimal schedule of ifosfamide should be repeated doses over several days. With the development of 5-day infusion devices, we developed and evaluated a 5-day infusion regimen of ifos...

journal_title：Cancer chemotherapy and pharmacology

authors： Coriat R,Mir O,Camps S,Ropert S,Billemont B,Leconte M,Larousserie F,Anract P,Alexandre J,Goldwasser F

更新日期：2010-02-01 00:00:00

abstract：PURPOSE:Pegylated liposomal doxorubicin (PLD) is used to treat patients with breast and gynecological cancers. In order to optimize treatment with PLD, we assessed the prognostic and predictive factors for efficacy of PLD. METHODS:Seventeen patients treated with PLD 30 or 40 mg/m(2) underwent pharmacokinetic sampling ...

journal_title：Cancer chemotherapy and pharmacology

authors： Boers-Sonderen MJ,van Herpen CM,van der Graaf WT,Desar IM,van der Logt MG,de Beer YM,Ottevanger PB,van Erp NP

更新日期：2014-09-01 00:00:00

abstract：PURPOSE:The activity of 5-fluorouracil (5-FU) against colon cancer is enhanced by leucovorin and the combination of 5-FU and levamisole has activity in the adjuvant treatment of colonic malignancies. The combination of 5-FU with both leucovorin and levamisole may provide additional benefit in the treatment of colon can...

journal_title：Cancer chemotherapy and pharmacology

authors： Cleary JF,Arzoomanian R,Alberti D,Feierabend C,Storer B,Witt P,Carbone P,Wilding G

更新日期：1997-01-01 00:00:00

abstract：PURPOSE:This study was conducted to define the activity of irofulven in the treatment of a series of xenografts derived from human glioblastoma multiforme growing subcutaneously and intracranially in athymic nude mice. METHODS:Athymic mice bearing subcutaneous or intracranial tumors were treated with irofulven at a 10...

journal_title：Cancer chemotherapy and pharmacology

authors： Friedman HS,Keir ST,Houghton PJ,Lawless AA,Bigner DD,Waters SJ

更新日期：2001-11-01 00:00:00

abstract：PURPOSE:To evaluate the plasma protein binding and pharmacokinetics of prednisolone during therapeutic use in children with acute lymphoblastic leukemia (ALL) using the population approach. METHODS:A two-compartment pharmacokinetic model was used to describe data from 23 children with ALL (aged 2-15 years). Prednisolo...

journal_title：Cancer chemotherapy and pharmacology

authors： Petersen KB,Jusko WJ,Rasmussen M,Schmiegelow K

更新日期：2003-06-01 00:00:00

abstract：:Pretreatment of the human lymphoblastoid cell line CCRF-CEM with 0.02 microM arabinosyl cytosine (ara C) enhances both the cytotoxic and the DNA-damaging effects of etoposide. This concentration of ara C is itself non-cytotoxic and results in no detectable DNA damage as measured by alkaline elution. Ara C pretreatment...

journal_title：Cancer chemotherapy and pharmacology

authors： Chresta CM,Hicks R,Hartley JA,Souhami RL

更新日期：1992-01-01 00:00:00

abstract：:Cytidine analogues such as cytosine arabinoside, gemcitabine, decitabine, 5-azacytidine, 5-fluoro-2'-deoxycytidine and 5-chloro-2'-deoxycytidine undergo rapid catabolism by cytidine deaminase (CD). 3,4,5,6-tetrahydrouridine (THU) is a potent CD inhibitor that has been applied preclinically and clinically as a modulato...

journal_title：Cancer chemotherapy and pharmacology

authors： Beumer JH,Eiseman JL,Parise RA,Florian JA Jr,Joseph E,D'Argenio DZ,Parker RS,Kay B,Covey JM,Egorin MJ

更新日期：2008-08-01 00:00:00

abstract：:A phase I trial of indicine-N-oxide was carried out in 12 children with solid tumors and in 16 with leukemia. Doses of 5, 6, and 7.5 g/m2 were given parenterally as a 15-min infusion every 3 weeks. The maximum tolerated dose in patients with solid tumors was 7.5 g/m2 and the dose-limiting toxicity was myelosuppression...

journal_title：Cancer chemotherapy and pharmacology

authors： Whitehead VM,Bernstein ML,Vega R,Vats T,Dyment P,Vietti TJ,Krischer J

更新日期：1990-01-01 00:00:00

abstract：PURPOSE:Recently, it was shown that chrysin causes upregulation of UGT1A1 in Caco-2 intestinal cells. Therefore, we proposed that oral chrysin may reduce irinotecan (CPT-11) induced diarrhoea by shifting the SN-38G/SN-38 equilibrium towards the inactive SN-38G in the gastrointestinal mucosa. The purpose of this study w...

journal_title：Cancer chemotherapy and pharmacology

authors： Tobin PJ,Beale P,Noney L,Liddell S,Rivory LP,Clarke S

更新日期：2006-02-01 00:00:00

abstract：BACKGROUND:The presence of hepatic portal venous gas (HPVG) is a rare finding. It is most commonly caused by bowel necrosis and typically carries a grave prognosis. Bevacizumab has emerged as an effective standard therapy in the frontline management of advanced non-small cell lung cancer (NSCLC). Although bevacizumab i...

journal_title：Cancer chemotherapy and pharmacology

authors： Ortega J,Hayes JM,Antonia S

更新日期：2009-12-01 00:00:00

abstract：:Dexniguldipine-HCl (DNIG)--a prospective clinical modulator of p170-glycoprotein (pgp170)-mediated multidrug resistance (MDR)--was evaluated in a drug-accumulation assay in MDR murine leukemia cell strain F4-6RADR expressing pgp170. The compound elevated low accumulation of either doxorubicin (DOX), daunorubicin (DNR)...

journal_title：Cancer chemotherapy and pharmacology

authors： Reymann A,Looft G,Woermann C,Dietel M,Erttmann R

更新日期：1993-01-01 00:00:00

abstract：:A three-compartment model was fitted to idarubicin data in a NONMEM pooled-data approach. Clearance (CL) of 221.7 ml/min was relatively high, and drug distribution was rapid (CLD = 248.3 ml/min) and extensive [steady-state volume of distribution (Vss) 24 1]. The area under the concentration-time curve (AUC) of idarbic...

journal_title：Cancer chemotherapy and pharmacology

authors： Looby M,Linke R,Weiss M

更新日期：1997-01-01 00:00:00

abstract：PURPOSE:Epigenetic agents are among the newly targeted therapeutic strategies being studied with intense interest for patients with multiple myeloma. Here, we demonstrate the antitumor activity of a phenylbutyrate-based histone deacetylase (HDAC) inhibitor, (S)-HDAC42, and identify its possible targets in myeloma cells...

journal_title：Cancer chemotherapy and pharmacology

authors： Bai LY,Omar HA,Chiu CF,Chi ZP,Hu JL,Weng JR

更新日期：2011-08-01 00:00:00

abstract：:A series of in vitro cytotoxicity studies were performed to achieve pharmacologic reversal of resistance to the alkylating agent mitomycin (MMC) in L-1210 leukemia cells. A multidrug-resistant (MDR), P-glycoprotein-positive cell line, RL-1210/.1 [11], was exposed to potential MDR modulators in the absence or presence ...

journal_title：Cancer chemotherapy and pharmacology

authors： Dorr RT,Liddil JD

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:Ibrutinib is an orally administered, irreversible Bruton's tyrosine kinase inhibitor for treatment of B-cell malignancy. This study evaluated the effects of single-dose ibrutinib at therapeutic and supratherapeutic exposures on cardiac repolarization in healthy subjects. METHODS:Part 1 used an open-label, two-...

journal_title：Cancer chemotherapy and pharmacology

authors： de Jong J,Hellemans P,Jiao JJ,Huang Y,Mesens S,Sukbuntherng J,Ouellet D

更新日期：2017-12-01 00:00:00

abstract：PURPOSE:Temozolomide (TMZ) is a widely used oral alkylating agent that has been associated with the development of severe hematologic adverse events (HAEs). Limited clinical information about HAEs is available. METHODS:We searched the FDA MedWatch database for TMZ and obtained all MedWatch reports on TMZ submitted to ...

journal_title：Cancer chemotherapy and pharmacology

authors： Villano JL,Letarte N,Yu JM,Abdur S,Bressler LR

更新日期：2012-01-01 00:00:00

abstract：PURPOSE:This study aimed at investigating the anti-tumor effect of arsenic sulfide (As2S2) against liver cancer both in vivo and in vitro and to elucidate its underlying mechanisms. METHODS:Cell viability of the human hepatocellular carcinoma cell lines SMMC-7721, BEL-7402, HepG2 were measured by CCK-8 assay. The effe...

journal_title：Cancer chemotherapy and pharmacology

authors： Wang S,Zhang C,Li Y,Li P,Zhang D,Li C

更新日期：2019-03-01 00:00:00

abstract：:Cultures of human colon carcinoma, HCT-8, were treated with millimolar concentrations of thymidine by different schedules designed to cytokinetically and biochemically modulate methotrexate (MTX) and 5-fluorouracil (FUra) toxicity. Thymidine (dThd)-synchronized HCT-8 cells monitored by flow cytofluorometry showed incr...

journal_title：Cancer chemotherapy and pharmacology

authors： Benz C,Choti M,Newcomer L,Cadman E

更新日期：1984-01-01 00:00:00

abstract：PURPOSE:Our study was designed to evaluate the efficacy and safety of everolimus in patients with pre-treated metastatic gastric and esophagus cancers in a US-based population focusing on biomarker correlation. METHODS:Patients with advanced upper GI adenocarcinomas who progressed after 1-2 prior regimens received eve...

journal_title：Cancer chemotherapy and pharmacology

authors： Wainberg ZA,Soares HP,Patel R,DiCarlo B,Park DJ,Liem A,Wang HJ,Yonemoto L,Martinez D,Laux I,Brennan M,Hecht JR

更新日期：2015-07-01 00:00:00

abstract：PURPOSE:We conducted phase I and tolerability studies to determine the maximum tolerated dose (MTD) and recommended dose of nab-paclitaxel when administered weekly with solid tumors and to evaluate the tolerability of weekly administration at a dose of 150 mg/m(2) with metastatic breast cancer (MBC) as a first-line the...

journal_title：Cancer chemotherapy and pharmacology

authors： Ando M,Yonemori K,Katsumata N,Shimizu C,Hirata T,Yamamoto H,Hashimoto K,Yunokawa M,Tamura K,Fujiwara Y

更新日期：2012-02-01 00:00:00